Successful pulp revascularization of an autotransplantated mature premolar with fragile fracture apicoectomy and plasma rich in growth factors: a 3‐year follow‐up

2019 ◽  
Vol 53 (3) ◽  
pp. 421-433 ◽  
Author(s):  
J. F. Gaviño Orduña ◽  
M. García García ◽  
P. Dominguez ◽  
J. Caviedes Bucheli ◽  
B. Martin Biedma ◽  
...  
Keyword(s):  
Growth Factors ◽  
Fragile Fracture ◽  
Pulp Revascularization

scholarly journals Use of Plasma Rich in Growth Factors and ReGeneraTing Agent Matrix for the Treatment of Corneal Diseases

Vision ◽  
2021 ◽  
Vol 5 (3) ◽  
pp. 34
Author(s):  
Ronald M. Sánchez-Ávila ◽  
Edmar Uribe-Badillo ◽  
Carlos Fernández-Vega González ◽  
Francisco Muruzabal ◽  
Borja de la Sen-Corcuera ◽  
...  
Keyword(s):  
Growth Factors ◽  
Corneal Ulcer ◽  
Disease Index ◽  
Eye Drops ◽  
Analog Scale ◽  
Ocular Surface Disease Index ◽  
Corneal Ulcers ◽  
Corrected Visual Acuity ◽  
The Mean

This study aimed to investigate the use of Plasma Rich in Growth Factors (PRGF) associated with tissue ReGeneraTing Agent (RGTA) drops for the treatment of noninfectious corneal ulcers. RGTA treatment was applied (one drop every two days); however, if ulcer closure was not achieved, PRGF eye drops treatment was added (four times/day). The time taken to reach the ulcer closure, the Best Corrected Visual Acuity (BCVA), intraocular pressure (IOP), Visual Analog Scale (VAS, in terms of frequency and severity of symptoms), and Ocular Surface Disease Index (OSDI) were evaluated. Seventy-four patients (79 eyes) were included, and the mean age was 56.8 ± 17.3 years. The neurotrophic corneal ulcer was the most frequent disorder (n = 27, 34.2%), mainly for herpes virus (n = 15, 19.0%). The time of PRGF eye drops treatment associated with the RGTA matrix was 4.2 ± 2.2 (1.5–9.0) months, and the follow-up period was 44.9 ± 31.5 months. The ulcer closure was achieved in 76 eyes (96.2%). BCVA, VAS and OSDI improved from the baseline (p < 0.001), and IOP remained unchanged (p = 0.665). RGTA and PRGF in noninfectious ulcers were effective and could be a therapeutic alternative for this type of corneal disease.

scholarly journals Fibrin-Plasma Rich in Growth Factors Membrane for the Treatment of a Rabbit Alkali-Burn Lesion

2021 ◽  
Vol 22 (11) ◽  
pp. 5564
Author(s):  
Ronald M. Sánchez-Ávila ◽  
Natalia Vázquez ◽  
Manuel Chacón ◽  
Mairobi Persinal-Medina ◽  
Agustín Brea-Pastor ◽  
...  
Keyword(s):  
Growth Factors ◽  
Positive Staining ◽  
Corneal Surface ◽  
Treatment Groups ◽  
Alkali Burn ◽  
Clinical Events ◽  
Chemically Induced ◽  
Epithelial Progenitor Cells ◽  
Histochemical Examination

The purpose of this work is to describe the use of Fibrin-Plasma Rich in Growth Factors (PRGF) membranes for the treatment of a rabbit alkali-burn lesion. For this purpose, an alkali-burn lesion was induced in 15 rabbits. A week later, clinical events were evaluated and rabbits were divided into five treatment groups: rabbits treated with medical treatment, with a fibrin-PRGF membrane cultured with autologous or heterologous rabbit Limbal Epithelial Progenitor Cells (LEPCs), with a fibrin-PRGF membrane in a Simple Limbal Epithelial Transplantation and with a fibrin-PRGF membrane without cultured LEPCs. After 40 days of follow-up, corneas were subjected to histochemical examination and immunostaining against corneal or conjunctival markers. Seven days after alkali-burn lesion, it was observed that rabbits showed opaque cornea, new blood vessels across the limbus penetrating the cornea and epithelial defects. At the end of the follow-up period, an improvement of the clinical parameters analyzed was observed in transplanted rabbits. However, only rabbits transplanted with cultured LEPCs were positive for corneal markers. Otherwise, rabbits in the other three groups showed positive staining against conjunctival markers. In conclusion, fibrin-PRGF membrane improved the chemically induced lesions. Nonetheless, only fibrin-PRGF membranes cultured with rabbit LEPCs were able to restore the corneal surface.

Growth Factors and HIV-Infection in Children

1993 ◽  
Vol 21 (6) ◽  
pp. 342-345 ◽  
Author(s):  
G V Zuccotti ◽  
P Flumine ◽  
V Locatelli ◽  
G Banderali ◽  
E Riva
Keyword(s):  
Growth Factors ◽  
Leukocyte Count ◽  
Combined Therapy ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Chronic Anaemia ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome ◽  
Stimulating Factor

Three children with acquired immunodeficiency syndrome (AIDS) and chronic anaemia and leucopenia were treated with 5 μg/kg recombinant granulocyte colony-stimulating factor subcutaneously three times a week and 50 IU/kg erythropoietin subcutaneously twice a week. The therapy was not interrupted during the follow-up period. All children showed an increase of leukocyte count and haemoglobin levels. No transfusion was necessary and the number of admissions into hospital fell. These results suggest that combined therapy with granulocyte colony-stimulating factor and erythropoietin may improve leukopenia and anaemia, which is not zidovudine-related, in children who have AIDS.

scholarly journals Allogeneic platelet-derived growth factors local injection in treatment of tennis elbow: a prospective randomized controlled study

2022 ◽  
Author(s):  
Mahmoud Ibrahim Kandil ◽  
Abdel-Salam Abdel-Aleem Ahmed ◽  
Rasha Shaker Eldesouky ◽  
Sherif Eltregy
Keyword(s):  
Growth Factors ◽  
Treatment Group ◽  
Tennis Elbow ◽  
Local Injection ◽  
Controlled Study ◽  
Saline Control ◽  
Control Group ◽  
Patient’S Satisfaction ◽  
Significant Difference

Abstract Purpose The purpose of this study aimed to evaluate the efficacy of local injection of allogeneic platelet-derived growth factors in treatment of patients with tennis elbow. Patients and methods This study included 120 tennis elbow patients randomly divided into two groups. The patients were locally injected with allogeneic growth factors (treatment group) or with normal saline (control group). The outcomes were assessed using Patient-Related Tennis Elbow Evaluation (PRTEE) and quick Disabilities of the Arm, Shoulder and Hand (qDASH) scales. The clinical outcomes were accordingly classified as excellent, good and poor. The patient’s satisfaction and adverse effects were also recorded. Results There was no statistically significant difference between the two groups regarding the age, gender, dominant arm or the pre-injection scores. At three month follow-up, the reductions in the mean PRTEE and qDASH scores were 88.7% and 70.6% in the treatment group versus 21.8% and 14.9% in the control group, respectively. At the last follow-up, the outcomes in the treatment group were excellent in 85% of patients and good in 15%, versus 8% and 32% in the control group. Overall, 95% were satisfied in the treatment group compared to 25% in control group. Forty patients in the treatment group experienced mild transient post-injection pain. Conclusion This study strongly suggests that local injection of allogeneic platelet-derived growth factors could be a promising safe treatment option for tennis elbow with significant pain relief, functional improvement and patient’s satisfaction. Yet, additional larger studies are needed to assess the durability of these outcomes.

scholarly journals Treatment of Noninfectious Corneal Disorders With Plasma Rich in Growth Factors and ReGenerating Agent Matrix

2020 ◽  
Author(s):  
Ronald Mauricio Sanchez-Avila ◽  
Edmar Uribe-Badillo ◽  
Carlos Fernandez-Vega Gonzalez ◽  
Francisco Muruzabal ◽  
Borja De la Sen Corcuera ◽  
...  
Keyword(s):  
Growth Factors ◽  
Adverse Events ◽  
Corneal Ulcer ◽  
Eye Drops ◽  
Ocular Surface Disease Index ◽  
Corneal Ulcers ◽  
Corrected Visual Acuity ◽  
The Mean ◽  
Mean Time

Abstract Background: To provide the efficacy and safety of Plasma Rich in Growth Factors (PRGF) associated with tissue ReGeneraTing Agent (RGTA) drops for the treatment of noninfectious corneal ulcers.Methods: This retrospective study included patients from Fernandez-Vega University Institute between 2010 and 2019, with noninfectious corneal ulcers and no response to standard treatments. RGTA treatment was firstly applied (1 drop every two days), but if ulcer closure was not achieved, PRGF eye drops treatment was added (4 times/day). The time to reach the ulcer closure; the Best Corrected Visual Acuity (BCVA), intraocular pressure (IOP), Visual Analog Scale (VAS, in frequency and severity of symptoms), and Ocular Surface Disease Index (OSDI) were evaluated. The presence of adverse events along the follow-up period was also reported. Results: Seventy-four patients (79 eyes) were included in the study, forty-six eyes (62.2%) were women, and the mean age was 56.8 ± 17.3 years. The neurotrophic corneal ulcer was the most frequent disorder found in the patients of the study (n = 27, 34.2%), mainly due to the herpes virus (n = 15, 19.0%). The mean time of PRGF eye drops treatment associated with RGTA matrix was 4.2 ± 2.2 (1.5 -9.0) months, and the follow-up period was 44.9 ± 31.5 months. The ulcer closure was achieved in 76 eyes (96.2%). BCVA, VAS and OSDI improved significantly from the baseline (p<0.001), while IOP remained unchanged (p=0.665). No adverse events were recorded. Conclusions: The use of RGTA and PRGF in noninfectious ulcers was effective and safe, and it could be a therapeutic alternative for this type of corneal diseases.

scholarly journals Alterations in the Levels of Growth Factors in Adolescents with Major Depressive Disorder: A Longitudinal Study during the Treatment with Fluoxetine

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
Enrique Becerril-Villanueva ◽  
Gilberto Pérez-Sánchez ◽  
Samantha Alvarez-Herrera ◽  
Manuel Iván Girón-Pérez ◽  
Rodrigo Arreola ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Growth Factors ◽  
Depressive Disorder ◽  
Healthy Volunteers ◽  
Neural Development ◽  
Rating Scale ◽  
Major Depressive ◽  
Basic Fgf ◽  
Gm Csf

Major depressive disorder (MDD) has a prevalence of 5% in adolescents. Several studies have described the association between the inflammatory response and MDD, but little is known about the relationship between MDD and growth factors, such as IL-7, IL-9, IL-17A, VEGF, basic FGF, G-CSF, and GM-CSF. It must be appointed that there are scarce reports on growth factors in adolescents with MDD and even fewer with a clinical follow-up. In this work, we evaluated the levels of growth factors (IL-7, IL-9, IL-17A, VEGF, basic FGF, G-CSF, and GM-CSF) in MDD adolescents and the clinical follow-up during eight weeks of treatment with fluoxetine. Methods. All patients were diagnosed according to the DSM-IV-TR, and the severity of the symptoms was evaluated using the Hamilton Depression Rating Scale (HDRS). Growth factors IL-7, IL-9, IL-17A, VEGF, basic FGF, G-CSF, and GM-CSF were quantified by cytometric bead array using serum samples from 22 adolescents with MDD and 18 healthy volunteers. Results. All patients showed clinical improvement since the fourth week of pharmacological treatment according to the HDRS. Considerably higher levels of IL-7, IL-9, IL-17A, VEGF, basic FGF, G-CSF, and GM-CSF were detected in MDD adolescents as compared to healthy volunteers. A significant but temporal decrease was detected in basic FGF, G-CSF, and GM-CSF at week four of fluoxetine administration. Conclusions. To the best of our knowledge, this is the first report to show alterations in the levels of growth factors, such as IL-7, IL-9, IL-17A, VEGF, basic FGF, G-CSF, and GM-CSF in MDD adolescents during eight weeks of clinical follow-up. These disturbances might be involved in the physiopathology of MDD since such growth factors have been proven to participate in the neural development and correct functioning of the CNS; therefore, subtle alterations in it may contribute to MDD.

Pulp revascularization of a necrotic permanent incisor using plasma rich in growth factors

2017 ◽  
pp. S32-32
Author(s):  
E Yanes Barroso ◽  
JF Gavino Orduna ◽  
JF Barrientos Delgado ◽  
J Lopez Lopez ◽  
JJ Segura-Egea
Keyword(s):  
Growth Factors ◽  
Pulp Revascularization

Ultrasound-Guided Meniscal Injection of Autologous Growth Factors: A Brief Report

Cartilage ◽  
2021 ◽  
pp. 194760352110373
Author(s):  
Berardo Di Matteo ◽  
Daniele Altomare ◽  
Riccardo Garibaldi ◽  
Agostino La Porta ◽  
Angelo Manca ◽  
...  
Keyword(s):  
Growth Factors ◽  
Symptomatic Relief ◽  
Arthroscopic Surgery ◽  
Young Patients ◽  
Meniscal Repair ◽  
Common Finding ◽  
Meniscal Tissue ◽  
Tissue Healing ◽  
Meniscus Degeneration

Meniscal degeneration is a common finding even in young patients’ knees, and it is regarded as a predictor for the onset of early osteoarthritis (OA). When symptomatic, it represents a challenge since arthroscopic surgery provides unpredictable results: recent evidence has shown that partial meniscectomy is not better than conservative management up to 2 years of follow-up, and the removal of meniscal tissue may accelerate OA progression toward OA. Intra-articular injection of corticosteroids or hyaluronic acid may help in providing temporary symptomatic relief, but no influence should be expected on the quality of the meniscal tissue. Biologic agents have been adopted to treat a variety of degenerative musculoskeletal pathologies, and the use of platelet-derived growth factors (GFs) has become routine. Preclinical studies have documented that platelet-derived GFs may play a beneficial role in stimulating meniscal repair and regeneration by triggering anabolic pathways and stimulating local mesenchymal stem cells from synovium. Furthermore, also mechanical stimulation (e.g., arthroscopic trephination or percutaneous needling) in the red-red or red-white zone may further promote tissue healing. The purpose of the present brief report is to describe the clinical outcomes at 18 months’ follow-up in a cohort of patients affected by symptomatic medial meniscus degeneration and treated by percutaneous needling plus intra- and perimeniscal injection of autologous conditioned plasma (ACP). The procedure was shown to be safe and provided significant pain reduction and improvement in subjective scores. This treatment option deserves further investigation in a comparative setting, to establish whether it could offer advantage over isolated intra-articular injections.

Oral Fludarabine and Cyclophosphamide Plus Rituximab in the Treatment of the Chronic Lymphocytic Leukemia.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 5039-5039
Author(s):  
Paolo Casula ◽  
Gabriele Sorano ◽  
Donatella Pulixi ◽  
Fabio Culurgioni ◽  
Emanuele Angelucci
Keyword(s):  
Growth Factors ◽  
Hospital Admission ◽  
Lymphocytic Leukemia ◽  
Oral Cyclophosphamide ◽  
Who Grade ◽  
Bulky Disease ◽  
Efficient Treatment ◽  
Heavy Chains ◽  
Intravenous Formulation

Abstract The association of Fludarabine, Cyclophospamide and Rituximab is the most efficient treatment for Chronich Lynphocitic Leukemia (CLL) but the intravenous formulation and the necessity of hospital admission limit its wide application. We tested the safety and feasibility of the association of oral Fludarabine and oral Cyclophosphamide with iv Rituximab in a outpatient setting in a group of CLL patients who could not be treated by standard therapy. Methods. From June 2004 to July 2005 eighteen patients were treated in the Hematology Department in Cagliari, Italy. Informed consent was obtained by all patients before entering the trial. Ten patients were males and 8 were females; median age was 62 years (range 31–74). Binet clinical stage was C in 6 patients and B in progression or with B symptoms or with bulky disease in the remaining twelve. All patients were CD5/CD19 positive and positive for the rearrangement of immunoglobulins heavy chains by polymerase chain reaction (PCR). Nine have been previously treated by 1–5 lines of chemotherapy and nine were untreated. Chemotherapy schedule consisted of oral Fludarabine 40 mg/m2 on days 1 to 3, oral Cyclophospamide 250 mg/m2 days 1 to 3 and Rituximab 375 mg/m2 i.v day 0 starting from the second course of chemotherapy. Courses were repeated every 28 days for a total of 6 cycles. All patients received broad spectrum anti-infective prophylaxis by levofloxacin 500 mg/day and fluconazol 100 mg/day. Results. The first twelve patients were treated without prophylactic growth factors and ten of them (83%) developed WHO grade 4 neutropenia requiring therapeutic growth factors (filgrastim/lenograstim for 3–6 days). Subsequently 6 patients received prophylactic peg-filgrastim in a single dose on day 4 in every course and none had WHO grade &gt;2 neutropenia There were no grade &gt;2 WHO organ toxicity nor toxic deaths. No life treating infection was registered and no hospital admission was required. Two patients (11%) interrupted the treatment because of side effects (one patient had reaction to Rituximab and one developed haemolytic anaemia). At the time of this writing 13 patients had completed the planned course of treatment in the scheduled time. Treatment is ongoing without major problems in the remaining three. Disease response was evaluated in these 13 patients. Eight (62%) obtained a complete, clinical and molecular, remission as documented by disappearance of the immunoglobulin heavy chains rearrangement by PCR while 5 (38%) obtained a very good partial response. Overall response rate was 100%. With a medium follow up of 6 months (range 1–8) no patients presented relapse or progression disease. Conclusion. The association of oral Fludarabine and oral Cyclophosphamide with Rituximab is a feasible treatment in outpatients setting with excellent patient compliance in association with prophylactic granulocyte growth factors. Preliminary efficacy results are not different to those obtained with standard intravenous formulation. Longer follow up is necessary to confirm efficacy.

scholarly journals A novel autologous-made matrix using hyaline cartilage chips and platelet-rich growth factors for the treatment of full-thickness cartilage or osteochondral defects: Preliminary results

2019 ◽  
Vol 28 (1) ◽  
pp. 230949901988754 ◽  
Author(s):  
Ramón Cugat ◽  
Eduard Alentorn-Geli ◽  
Jordi Navarro ◽  
Xavier Cuscó ◽  
Gilbert Steinbacher ◽  
...  
Keyword(s):  
Growth Factors ◽  
Magnetic Resonance ◽  
Surgical Technique ◽  
Hyaline Cartilage ◽  
Lysholm Score ◽  
Osteochondral Defects ◽  
Full Thickness ◽  
Cartilage Restoration ◽  
Subjective Form

Purpose: To report the clinical, functional, and magnetic resonance imaging (MRI)-based outcomes of a novel autologous-made matrix consisting of hyaline cartilage chips combined with mixed plasma poor rich in platelets clot and plasma rich in growth factors (PRGF) for the treatment of knee full-thickness cartilage or osteochondral defects. Methods: Between July 2015 and January 2018, all patients with full-thickness cartilage or osteochondral defects undergoing this novel cartilage restoration surgical technique were approached for eligibility. Indications for this procedure included traumatic or atraumatic full-thickness knee cartilage defects or osteochondritis dissecans. Patients were included if they had no concomitant use of stem cells, previous ipsilateral cartilage repair procedure, or follow-up was less than 10 months. The outcomes included data on current symptoms, physical exam, patient-reported, and functional outcomes (visual analogue scale (VAS) for pain, Lysholm score, Tegner activity scale, International Knee Documentation Committee (IKDC) subjective form, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, Lequesne index, and short form-12 (SF-12)) and the magnetic resonance observation of cartilage repair tissue (MOCART) score. These outcomes were compared to preoperative values, except for the MOCART score. Results: Fifteen patients were included in this preliminary study: mean (standard deviation (SD), range) follow-up 15.9 months (7.2, 10–32), age 26.8 years (12.1, 16–58), and body mass index 23.2 (2.1, 19.3–26.9). There were 14 men (93%) and 1 woman (7%). There was a statistically significant improvement between pre- and postoperative periods for VAS for pain ( p = 0.003), Lysholm score ( p = 0.002), IKDC subjective form ( p = 0.003), WOMAC for pain ( p = 0.005), WOMAC for stiffness ( p = 0.01), WOMAC for function ( p = 0.002), Lequesne Index ( p = 0.002), and SF-12 physical component summary ( p = 0.007). The postoperative mean (SD; range) MOCART score was 70 (12.4; 40–85). Conclusions: The use of this novel cartilage restoration surgical technique provides excellent clinical, functional, and MRI-based outcomes in young, active individuals with full-thickness cartilage or osteochondral defects. Level of evidence: Level IV—Therapeutic case series.

Sign in / Sign up

Export Citation Format

Share Document